Navigating the PFAS Challenge in Pharma: Regulatory Landscape, Risk Management, and Health Implications
Complimentary
Learning Level: Intermediate
Time: 1000 - 1100 EDT
Session Length: 1 hour
Per- and polyfluoroalkyl substances (PFAS) have become a significant concern in the pharmaceutical industry due to their persistence in the environment, potential health risks, and extensive applications in pharmaceutical manufacturing. This webinar, organized by the ISPE Sustainability Community of Practice (CoP), brings together experts from leading pharmaceutical companies to discuss the latest regulatory developments and strategies in managing PFAS. This session will serve as an introduction to a broader discussion about PFAS at the EU ISPE conference in May.
Learning Objective
- Sarah Ebadi (Roche) - PFAS Regulatory Landscape (15 mins) Sarah will provide an overview of the global regulatory landscape for PFAS, highlighting key regulations and compliance requirements that pharmaceutical companies must navigate.
- Kelly LaCarubba (Takeda) - Case Study: Managing PFAS Risks in Pharma (15 mins) Kelly will present a case study on Takeda's approach to assessing and managing PFAS risks. She will share insights into the company's risk assessment strategy, ongoing projects, and lessons learned.
- Franz-Manfred Schuengel (Merck) - PFAS, Health, and Sustainability (15 mins) Franz-Manfred will discuss the health implications of PFAS exposure and the importance of sustainability in addressing these challenges. He will explore the intersection of health, environmental impact, and sustainable practices in the pharmaceutical industry.
